ProterixBio operates a high-complexity, CLIA-certified clinical testing laboratory. We have expertise in the development and validation of quantitative clinical assays for inflammation, immune response and a variety of other disease pathways. If you are interested in a CLIA testing partner or a clinical test development partner or need to establish an assay for a clinical trial, possibly including remote blood collection, please contact us. In addition to our assay development services, we develop and commercialize diagnostic solutions that address critical unmet needs in population health and chronic care. An area of focus has been vulnerable populations such as those with chronic obstructive pulmonary disease, diabetes and cardiovascular disease. The company has developed algorithms utilizing combinations of blood-based biomarkers for identifying individuals at high risk for severe outcomes. ProterixBio maintains a rigorous approach to test development that includes collaborating with leading academic medical centers and validating assays in large, carefully curated cohorts. ProterixBio is headquartered in Billerica, Massachusetts.